Excelsior Sciences Raises $95M to Replace Human Chemists with AI Robots for Drug Discovery
Summary
Excelsior Sciences secures $95 million to revolutionize drug discovery by replacing human chemists with AI-powered robots that break down FDA-approved molecules into 'smart bloccs' and reassemble them into new pharmaceutical compounds, promising faster and cheaper development while reshoring manufacturing to the US.
Key Points
- Excelsior Sciences secures $95 million in Series A funding to develop new drugs using AI and robotic automation instead of human chemists
- The company breaks down FDA-approved molecules into building blocks called 'smart bloccs' that robots can reassemble into new drug compounds
- Excelsior aims to reshore pharmaceutical manufacturing to the US by offering faster and cheaper automated drug discovery services to biotech companies